New 'Double-Target' cell therapy fights Tough-to-Treat blood cancer

NCT ID NCT05826535

Recruiting now Disease control Sponsor: Lyell Immunopharma, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing a new, experimental cell therapy called LYL314 for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The therapy, a type of CAR-T, is designed to attack cancer cells by targeting two markers (CD19 and CD20) instead of one, which may help prevent the cancer from evading treatment. The main goals are to find a safe dose and see how well it works to shrink or eliminate the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Augusta University Medical Center
RECRUITING

Augusta, Georgia, 30912, United States
Baylor University Medical Center
RECRUITING

Dallas, Texas, 75246, United States
Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Corewell Health
RECRUITING

Grand Rapids, Michigan, 49503, United States
Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States
Indiana Blood and Marrow Transplantation
RECRUITING

Indianapolis, Indiana, 46237, United States
Intermountain Healthcare
RECRUITING

Salt Lake City, Utah, 84143, United States
Lehigh Valley Topper Cancer Center Institute
RECRUITING

Allentown, Pennsylvania, 18103, United States
Louisiana State University Health Sciences Center
RECRUITING

Shreveport, Louisiana, 71130, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Montefiore Medical Center
RECRUITING

The Bronx, New York, 10461, United States
Roswell Park Comprehensive Cancer Center
RECRUITING

Buffalo, New York, 14263, United States
Scripps Clinic
RECRUITING

San Diego, California, 92037, United States
Texas Transplant Institute
RECRUITING

San Antonio, Texas, 78229, United States
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of California, Los Angeles (UCLA) Medical Center
RECRUITING

Los Angeles, California, 90095, United States
University of California-Irvine Medical Center
RECRUITING

Irvine, California, 92697, United States
University of Cincinnati (UC) Physicians Company, LLC
RECRUITING

Cincinnati, Ohio, 45267, United States
University of Iowa
RECRUITING

Iowa City, Iowa, 52242, United States
University of Louisville Brown Cancer Center
RECRUITING

Louisville, Kentucky, 40202, United States
University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States
University of New Mexico Comprehensive Cancer Center
RECRUITING

Albuquerque, New Mexico, 87131, United States
Virginia Commonwealth University-Massey Cancer Center
RECRUITING

Richmond, Virginia, 23298, United States
Virginia Oncology Associates
RECRUITING

Norfolk, Virginia, 24502, United States
West Penn Hospital
RECRUITING

Pittsburgh, Pennsylvania, 15224, United States

Conditions

Explore the condition pages connected to this study.

LARGE B-CELL LYMPHOMA NON-HODGKIN LYMPHOMA REFRACTORY NON-HODGKIN LYMPHOMA RELAPSED NON HODGKIN LYMPHOMA